Rusch V, Hyde R M, Luckey T D
Prog Food Nutr Sci. 1983;7(3-4):39-52.
Vaccines of non-pathogenic intestinal bacteria for oral administration have been used in the therapy of chronic and recurrent infections by the German Medical Association for Microbiological Therapy for over three decades. Three different oral bacterial vaccines were used in particular: 1. A sterile autolysate of non-pathogenic S. faecalis and E. coli; 2. a viable non-pathogenic S. faecalis vaccine, and; 3. a viable non-pathogenic E. coli vaccine. Clinical studies indicate the safety and efficacy of these bacterial products, and suggest the stimulation of immune activities and competitive capacities of S. faecalis and E. coli as mode of action. In animal experiments, orally administered intestinal bacterial vaccines enhance the resistance of mice against subsequent challenge with lethal doses of Salmonella typhimurium and Haemophilus influenzae. Mice were allowed access to a viable suspension of either S. faecalis or E. coli for at least 3 weeks. They were then challenged with either of the two unrelated pathogens. Both pre-treatment procedures conferred significant protection of the animals. The mechanism of this protective action appears to involve modification of white blood cell kinetics in the mice. The peritoneal resident cell population in mice is significantly increased by S. faecalis treatment.
三十多年来，德国微生物疗法医学协会一直使用口服非致病性肠道细菌疫苗来治疗慢性和复发性感染。特别使用了三种不同的口服细菌疫苗：1. 非致病性粪肠球菌和大肠杆菌的无菌自溶产物；2. 活的非致病性粪肠球菌疫苗；3. 活的非致病性大肠杆菌疫苗。临床研究表明了这些细菌产品的安全性和有效性，并表明刺激粪肠球菌和大肠杆菌的免疫活性和竞争能力是其作用方式。在动物实验中，口服肠道细菌疫苗可增强小鼠对随后致死剂量鼠伤寒沙门氏菌和流感嗜血杆菌攻击的抵抗力。让小鼠接触粪肠球菌或大肠杆菌的活悬液至少3周。然后用这两种无关病原体中的任何一种对它们进行攻击。两种预处理程序都能显著保护动物。这种保护作用的机制似乎涉及小鼠白细胞动力学的改变。粪肠球菌治疗可使小鼠腹腔常驻细胞数量显著增加。
